DEFA14A 1 cue-defa14a_20210609.htm DEFA14A cue-defa14a_20210609.htm






Washington, D.C. 20549




(Rule 14a-101)



Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No.    )



Filed by the Registrant                              Filed by a Party other than the Registrant  

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Rule 14a-12




(Name of Registrant as Specified in its Charter)


(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.










Title of each class of securities to which transaction applies: N/A









Aggregate number of securities to which transaction applies: N/A









Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A









Proposed maximum aggregate value of transaction: N/A









Total fee paid: N/A




Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.










Amount Previously Paid: N/A









Form, Schedule or Registration Statement No.: N/A









Filing Party: N/A









Date Filed: N/A











Cue Biopharma, Inc. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be held on June 09, 2021 For Stockholders as of record on April 12, 2021 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy materials, and to obtain directions to attend meeting, go to: To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.  For a convenient way to view proxy materials and VOTE go to  Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.  If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 26, 2021.  To order paper materials, use one of the following methods.  When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.  * If requesting material by e-mail, please send a blanke-mail with the 12 digit control number (located above)in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.  Cue Biopharma, Inc.  Meeting Type: Annual Meeting of Stockholders  Date: Wednesday, June 09, 2021  Time: 11:00 AM, Eastern Time  Place: Annual Meeting to be held live via the internet  Please visit for more details.  You must pre-register to attend the meeting online and/or participate at  SEE REVERSE FOR FULL AGENDA   INTERNET   TELEPHONE (866)648-8133   *E-MAIL







Cue Biopharma, Inc.  Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL  1. Election of seven directors to our board of directors, each to serve until the 2022 annual meeting of stockholders 1.01 Daniel R. Passeri 1.02 Frank Morich 1.03 Frederick Driscoll 1.04 Aaron Fletcher 1.05 Cameron Gray 1.06 Tamar Howson 1.07 Peter Kiener 2. The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.